A Double-Blind, Randomized, Parallel, Placebo-Controlled Trial Assessing the Analgesic Efficacy of a Single Dose of Fast Release Aspirin 1000 mg and Acetaminophen 1000 mg in Tension Type Headache Pain

Bayer1 site in 1 country9 target enrollmentMarch 12, 2012

ConditionsHeadache

InterventionsAcetylsalicylic acid (Aspirin, BAY1019036)Acetaminophen Placebo

DrugsAcetylsalicylic acid (Aspirin, BAY1019036)Acetaminophen Placebo

Overview

Phase: Phase 3
Intervention: Acetylsalicylic acid (Aspirin, BAY1019036)
Conditions: Headache
Sponsor: Bayer
Enrollment: 9
Locations: 1
Primary Endpoint: Time to meaningful pain relief (defined as the time when the subject indicates pain relief that is meaningful to the subject)
Status: Terminated
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this trial is to determine if a single, oral dose of a fast release aspirin 1000 mg provides relief compared to acetaminophen 1000 mg and placebo in subjects with tension-type headache pain.

Registry

clinicaltrials.gov

Start Date

March 12, 2012

End Date

June 4, 2012

Last Updated

7 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Bayer

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Healthy, ambulatory, male and female volunteers ages 18-65 years old
•History of an onset of tension type headaches before age 50
•Experiencing over the last year ≥ 4 tension type headaches of at least moderate intensity per month and with the majority of headaches lasting greater than three hours, that meet commonly recognized criteria for diagnosis per the International Headache Society
•History of response to treatment with over-the-counter (OTC) analgesics
•Understand the pain rating scales (as judged by the trial coordinator)
•Present with at least moderate headache pain on a 0-10 point numerical rating scale (a score of at least 4 on an 11 point scale ranging from 0 to 10) at the Treatment Visit
•Onset of pain within three hours of the Treatment Visit
•Confirmation by a physician of acute tension type headache symptoms as described by the International Headache Society diagnostic criteria

Exclusion Criteria

•History of hypersensitivity to aspirin, salicylates, other NSAIDs, acetaminophen, and similar pharmacological agents or components of the investigational products, including the placebo
•Use of any immediate release analgesic/anti-pyretic within four hours or use of any sustained release or long acting analgesic/anti-pyretic within 12 hours proceeding administration of Investigational Product
•Presence of symptoms that are consistent with menstrual headache or migraine headache as described by the International Headache Society diagnostic criteria
•History of migraine headaches more than once per month
•Relevant concomitant disease such as asthma (exercise induced asthma is permitted), chronic sinusitis or nasal structural abnormalities causing greater than 50 percent obstruction (polyposis nasi, marked septal deviation) that can interfere with the conduct of the trial in the judgment of the Investigator
•Current or past history of bleeding disorder(s)
•History of gastrointestinal bleeding or perforation, related to previous Nonsteroidal Anti-inflammatory Drugs (NSAID) therapy. Active, or history of recurrent peptic ulcer/hemorrhage (two or more distinct episodes of proven ulceration or bleeding)
•Recent head or neck trauma (within 2 weeks)
•Current use of blood thinning (anticoagulant), low dose aspirin, or steroid drug

Arms & Interventions

Arm 1

Intervention: Acetylsalicylic acid (Aspirin, BAY1019036)

Arm 2

Intervention: Acetaminophen

Arm 3

Intervention: Placebo

Outcomes

Primary Outcomes

Time to meaningful pain relief (defined as the time when the subject indicates pain relief that is meaningful to the subject)

Time Frame: Up to 2 hours post-dose

Secondary Outcomes

Time to first intake of rescue medication(Up to 2 hours)
Time to first perceptible relief(Up to 2 hours post-dose)
Time to first perceptible relief confirmed(Up to 2 hours post-dose)
Change from baseline in pain intensity score at different time points (on an 11-point Categorical Pain Intensity Scale, 0 = no pain, 10 = severe pain)(At baseline, 30, 60, 90 and 120 minutes post-dose, and immediately prior to the use of any rescue medication)
Summed time weighted of Pain Intensity Differences (PID) scores over 2 hours (SPID0-2)(Up to 2 hours)
Summed time weighted total pain relief scores over first hour (TOTPAR0-1)(Up to 1 hour)
Summed time weighted of Total Pain Relief Scores (TOTPAR) scores over 2 hours (TOTPAR0-2)(Up to 2 hours)
Pain Relief on 5-point Categorical Scale (0 = no relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, and 4 = complete relief)(At 30, 60, 90 and 120 minutes post-dose, and immediately prior to the use of any rescue medication)
Summed time weighted of Pain Intensity Differences (PID) scores over first hour (SPID0-1)(Up to 1 hour)
Summed, time weighted of Pain Relief and Pain Intensity Differences (PID) over 2 hours (SPRID0-2)(Up to 2 hours)
Summed, time weighted of Pain Relief and Pain Intensity Differences (PID) over first hour (SPRID0-1)(Up to 1 hour)
Global assessment of the investigational product as a pain reliever: 0 = poor, 1 = fair, 2 = good, 3 = very good or 4 = excellent(At 2 hours post-dose or immediately before the first intake of rescue medication, whichever is earlier)
Cumulative proportion of subjects taking rescue medication by time point(Up to 2 hours)
Safety variable will be summarized using descriptive statistic based on adverse events collection(Up to 5 days post-dose)